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THE adaptive response of the immune system, leading 
on one hand to immunity, or alternatively to nonre-
activity, and frequently to gradations in between these 
extremes, is determined primarily by antigen migration and 
localization, in contradistinction to antigen per se. 1 This 
conclusion has been reached through separate lines of 
evidence. The first began in 1992 with the previously 
overlooked finding of donor leukocyte chimerism in organ 
transplant recipients? The second came from observations 
following experimental infections, with emphasis on the 
importance of the transport and localization of live micro-
bial antigen (viral, bacterial, and protozoan). 
In both circumstances, there are two potential mecha-
nisms of nonresponsiveness: clonal exhaustion/deletion and 
immune indifference. The kinetics of the migratory antigen, 
leading on average to acute immune reactivity, or to 
immune indifference at one extreme and exhaustion/dele-
tion at the other are influenced by dose, timing, route, and 
localization of the migratory antigen. Although the relation 
between infectious and transplantation immunity is compli-
cated by the presence of a double immune reaction after 
transplantation (host vs graft and graft vs host) and the 
additional factor of immunosuppression, the two mecha-
nisms of acquired tolerance and the rules by which they 
operate are fundamentally the same. 
This concept exposes the meaning of acquired immlmo-
logic tolerance as first produced in a transplant setting 44 
years ago by Billingham et al. and relates such tolerance to 
the "allograft acceptance" that we see daily in practice. The 
enigmatic pattern of immunologic confrontation and reso-
lution seen in organ recipients was explained by responses 
of coexisting donor and recipient immune cells, each to the 
other, causing reciprocal clonal expansion, followed by 
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peripheral clonal deletion.1 An additional role of immune 
indifference was suggested by the replacement of donor by 
recipient leukocytes in the transplanted organ (rendering 
the graft less antigenic) and by ubiquitous distribution of 
the migratory donor leukocytes in the skin, host parenchy-
mal organs, and other nonlymphoid areas where they may 
be sequestered from CTL and neutralizing antibodies. 
Increasingly potent baseline immune suppressants have 
allowed these changes in the host/graft relationship to be 
engineered more efficiently and safely. This has been re-
flected in a stepwise improvement of patient and graft 
survival-from zero to feasible but unsatisfactory with 
azathioprine, striking improvement with the advent of 
cyclosporine (CyA), and another dramatic one with FK506. 
These spurts, made possible with better drugs, have been 
seen with all whole organs and also with bone marrow 
transplantation. Because FK506 can efficiently rescue the 
majority of CyA failures, the availability of FK506 has 
systematically upgraded program performance even when it 
has not been used from the outset as the baseline immu-
nosuppressant.3 
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